New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareNAD+ vs Liraglutide

NAD+ vs Liraglutide

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
NAD+
GLP-1 / Weight Loss AgonistsFat Loss & Metabolic
Liraglutide
Summary
NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme found in all living cells that declines dramatically with age. It is critical for energy metabolism, DNA repair, and sirtuin activation. IV and subcutaneous NAD+ supplementation is used in anti-aging protocols and addiction recovery programs.
Liraglutide is a long-acting GLP-1 receptor agonist approved for type 2 diabetes (Victoza) and chronic weight management (Saxenda). It reduces appetite, slows gastric emptying, improves insulin secretion, and promotes weight loss of 5–10% in clinical trials.
Half-Life
Varies by route; IV provides direct cellular delivery
~13 hours (once-daily dosing)
Admin Route
IV, SubQ, Oral
SubQ
Research
Typical Dose
500–1000 mg
Start 0.6 mg, titrate to 3 mg
Frequency
Daily for 4–10 days (loading), then monthly maintenance
Once daily
Key Benefits
  • Restored cellular energy production (ATP)
  • Sirtuin activation for longevity and metabolic regulation
  • Enhanced DNA repair capacity
  • Improved mitochondrial function and biogenesis
  • Cognitive clarity and mental energy
  • Reduced inflammation
  • Addiction withdrawal support (opioids, alcohol, benzodiazepines)
  • Improved sleep quality
  • Enhanced athletic endurance
  • Promotes weight loss (5–10% average)
  • Reduces appetite and caloric intake
  • Improves blood glucose control (HbA1c reduction)
  • Reduces cardiovascular events in T2DM (LEADER trial)
  • Slows gastric emptying
  • FDA-approved for T2DM and chronic weight management
  • Cardioprotective effects shown in clinical trials
  • May improve fatty liver (NAFLD/NASH)
Side Effects
  • Flushing and warmth during IV infusion
  • Nausea during rapid IV administration
  • Chest tightness (from rapid infusion — slow the rate)
  • Injection site irritation (subcutaneous)
  • +1 more
  • Nausea (very common, especially initially)
  • Vomiting
  • Diarrhea or constipation
  • Decreased appetite
  • +5 more
Stacks With